C-FKWTcell therapy, regenerative medicine, stem cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evaluate safety and efficacy of Longeveron mesenchymal stem cells in subjects with metabolic syndrome and assess effects on endothelial function.
Phase 2b randomized, placebo-controlled clinical trial testing several doses of Longeveron Mesenchymal Stem Cells.
ClinicalTrials.gov record describes a phase 2b SIRONA trial.
Evaluate whether Lomecel-B can improve outcomes and right-ventricle performance as adjunct therapy in patients with hypoplastic left heart syndrome.
Allogeneic mesenchymal stem cells delivered by intramyocardial injection during stage II bidirectional cavopulmonary anastomosis surgery; phase I safety trial followed by phase IIb evaluation.
Final ELPIS I data were published in a peer-reviewed journal in 2023, and a phase IIb clinical trial is listed for HLHS.
ELPIS phase I reported no major adverse cardiac events, 100% transplant-free survival at 1 year, and cardiac imaging signals suggesting possible favorable right-ventricle effects.
Test the safety of Lomecel-B in adults with mild to severe acute respiratory distress syndrome due to COVID-19 or influenza infection.
Phase I double-blind, randomized, placebo-controlled study of Lomecel-B in ARDS.
ClinicalTrials.gov record describes a phase I RECOVER study.
Test whether Lomecel-B can safely improve vaccine-specific antibody response in subjects with aging frailty.
Phase I/II randomized, blinded, placebo-controlled study of Lomecel-B for improving vaccine immune response.
ClinicalTrials.gov record describes a phase I/II trial in aging frailty vaccine response.
Evaluate whether laromestrocel improves physical functioning and patient-reported outcomes in ambulatory older adults with aging frailty.
Randomized, placebo-controlled, double-blind, multicenter phase 2b dose-escalation trial using human bone marrow-derived allogeneic mesenchymal stem cells.
Phase 2b aging frailty results were published in 2026.
The trial reported clinically meaningful dose- and time-dependent increases in 6-minute walk distance versus placebo, correlation with PROMIS Physical Function, and dose-associated decreases in soluble TIE2 as a potential biomarker of response.
Evaluate safety and potential efficacy of laromestrocel in slowing clinical progression, brain atrophy, and neuroinflammation in Alzheimer's disease.
Randomized, double-blind, placebo-controlled phase 2a trial of bone-marrow-derived allogeneic mesenchymal stem-cell therapy with single or multiple laromestrocel infusions.
Phase 2a results were published in Nature Medicine in 2025.
The study met its primary safety endpoint, reported no infusion-related reactions, hypersensitivities, or amyloid-related imaging abnormalities, and showed signals of improved clinical assessments, slowed whole-brain and hippocampal volume decline, and reduced neuroinflammation.
Develop allogeneic cellular therapies for life-threatening and chronic aging-related conditions, with programs in HLHS, Alzheimer's disease, aging frailty, and other indications.
Bone marrow-derived allogeneic mesenchymal stem-cell therapy/regenerative medicine platform evaluated across multiple clinical indications.
Company pipeline lists laromestrocel/Lomecel-B across HLHS, Alzheimer's disease, aging frailty, and pediatric dilated cardiomyopathy, with multiple clinical-stage studies and publications.
Evidence across supplied trials supports clinical evaluation of laromestrocel/Lomecel-B as a cell therapy platform, including safety findings and efficacy signals in Alzheimer's disease, HLHS, and aging frailty.